This study assessed whether the newly developed PET radioligands 11C-PS13 and 11C-MC1 could image constitutive levels of cyclooxygenase (COX)-1 and COX-2, respectively, in rhesus monkeys. Methods: After intravenous injection of either radioligand, 24 whole-body PET scans were performed. To measure enzyme-specific uptake, scans of the 2 radioligands were also performed after administration of a nonradioactive drug preferential for either COX-1 or COX-2. Concurrent venous samples were obtained to measure parent radioligand concentrations. SUVs were calculated from 10 to 90 min. Results: 11C-PS13 showed specific uptake in most organs, including spleen, gastrointestinal tract, kidneys, and brain, which was blocked by COX-1, but not COX-2, preferential inhibitors. Specific uptake of 11C-MC1 was not observed in any organ except the ovaries and possibly kidneys. Conclusion: The findings suggest that 11C-PS13 has adequate signal in monkeys to justify its extension to human subjects. In contrast, 11C-MC1 is unlikely to show significant signal in healthy humans, though it may be able to do so in inflammatory conditions.
This study assessed whether the newly developed PET radioligands 11C-PS13 and 11C-MC1 could image constitutive levels of cyclooxygenase (COX)-1 and COX-2, respectively, in rhesus monkeys. Methods: After intravenous injection of either radioligand, 24 whole-body PET scans were performed. To measure enzyme-specific uptake, scans of the 2 radioligands were also performed after administration of a nonradioactive drug preferential for either COX-1 or COX-2. Concurrent venous samples were obtained to measure parent radioligand concentrations. SUVs were calculated from 10 to 90 min. Results:11C-PS13 showed specific uptake in most organs, including spleen, gastrointestinal tract, kidneys, and brain, which was blocked by COX-1, but not COX-2, preferential inhibitors. Specific uptake of 11C-MC1 was not observed in any organ except the ovaries and possibly kidneys. Conclusion: The findings suggest that 11C-PS13 has adequate signal in monkeys to justify its extension to human subjects. In contrast, 11C-MC1 is unlikely to show significant signal in healthy humans, though it may be able to do so in inflammatory conditions.
Authors: Barbara K Martin; Christine Szekely; Jason Brandt; Steven Piantadosi; John C S Breitner; Suzanne Craft; Denis Evans; Robert Green; Michael Mullan Journal: Arch Neurol Date: 2008-05-12
Authors: Mackenzie A Michell-Robinson; Hanane Touil; Luke M Healy; David R Owen; Bryce A Durafourt; Amit Bar-Or; Jack P Antel; Craig S Moore Journal: Brain Date: 2015-03-29 Impact factor: 13.501
Authors: Md Jashim Uddin; Brenda C Crews; Kebreab Ghebreselasie; Imran Huda; Philip J Kingsley; Mohammad Sib Ansari; Mohammed N Tantawy; Jeffery Reese; Lawrence J Marnett Journal: Cancer Prev Res (Phila) Date: 2011-09-07
Authors: R Langenbach; S G Morham; H F Tiano; C D Loftin; B I Ghanayem; P C Chulada; J F Mahler; C A Lee; E H Goulding; K D Kluckman; H S Kim; O Smithies Journal: Cell Date: 1995-11-03 Impact factor: 41.582
Authors: S G Morham; R Langenbach; C D Loftin; H F Tiano; N Vouloumanos; J C Jennette; J F Mahler; K D Kluckman; A Ledford; C A Lee; O Smithies Journal: Cell Date: 1995-11-03 Impact factor: 41.582
Authors: Ansel T Hillmer; David Matuskey; Yiyun Huang; Nabeel Nabulsi; Jim Ropchan; Richard E Carson; Stephanie S O'Malley; Kelly P Cosgrove Journal: J Nucl Med Date: 2020-01-31 Impact factor: 10.057
Authors: Jeffrey H Meyer; Simon Cervenka; Min-Jeong Kim; William C Kreisl; Ioline D Henter; Robert B Innis Journal: Lancet Psychiatry Date: 2020-10-21 Impact factor: 27.083
Authors: Poorva Jain; Aisling M Chaney; Mackenzie L Carlson; Isaac M Jackson; Anoushka Rao; Michelle L James Journal: J Nucl Med Date: 2020-07-03 Impact factor: 10.057
Authors: Bruny V Kenou; Lester S Manly; Sara B Rubovits; Somachukwu A Umeozulu; Maia G Van Buskirk; Andrea S Zhang; Victor W Pike; Paolo Zanotti-Fregonara; Ioline D Henter; Robert B Innis Journal: J Nucl Med Date: 2022-06 Impact factor: 11.082
Authors: Amanda J Boyle; Junchao Tong; Sami S Zoghbi; Victor W Pike; Robert B Innis; Neil Vasdev Journal: J Nucl Med Date: 2020-09-25 Impact factor: 10.057